ClinicalTrials.gg
RecruitingNCT05796739SMART-EXAMUpdated Jan 14, 2025

Routine Versus As-Needed Stress Testing in Asymptomatic Patients With High-Risk Coronary Calcium

An interventional study of Non-invasive stress test and Medical treatment without further testing in Coronary Atherosclerosis Due to Calcified Coronary Lesion, sponsored by Samsung Medical Center. Recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-01-14.

Sponsored by Samsung Medical Center · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
3,000
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Coronary Artery Disease by Samsung Medical Center — 10 open to participants now, 14 under way, none of them phase 3. Coronary Artery Disease · Samsung Medical Center.

Planned enrollment
3rd of 21
3,000 · median 520
Started
2023
with 2 others
No phase
16 of 31
5 open now
Primary completion
2029-06
later than 9 of 13 live
Registered
20th of 31
by date

Among the 31 studies in Coronary Artery Disease by Samsung Medical Center, this one is the 3rd largest by planned enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2023, is one of 16 with no phase, reaches primary completion later than 9 of the 13 other live ones, and was the 20th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

10 of the 31 studies in Coronary Artery Disease by Samsung Medical Center are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Coronary Artery Disease by Samsung Medical Center, or all of them as a file.
02

Study summary

The purpose of the SMART-EXAM (SMart Angioplasty Research Team-Pragmatic Randomized Trial for Comparing Routine versus As-Needed EXercise or Pharmacologic Stress Testing in Asymptomatic Patients with High-Risk Coronary CalciuM) trial is to compare the major adverse cardiovascular events between routine stress testing and as-needed stress testing in asymptomatic patients with high-risk coronary calcium (Agatston Score ≥ 400) without proven ASCVD.

Read the detailed description

The coronary artery calcium (CAC) scan, a marker of subclinical coronary atherosclerosis, has become popular for individuals at risk for atherosclerotic cardiovascular disease. CAC is strongly associated with atherosclerotic burden and predicts coronary heart disease events and mortality, regardless of their age, sex, race, or atherosclerotic cardiovascular disease (ASCVD) risk. Furthermore, the progression of CAC is associated with an increased risk for future hard and total coronary heart disease events. The use of CAC scoring was associated with significant improvements in the reclassification and discrimination of incident ASCVD. Nevertheless, the current guidelines recommend CAC measurement for selected cases only with borderline or intermediate risk of ASCVD. However, in real-world practice, CAC testing is increasingly being promoted to the public as a means of self-assessment of cardiovascular risk and is widely being used regardless of ASCVD risk.

Non-invasive stress testing is often recommended to exclude potentially dangerous coronary artery disease. However, stress testing in asymptomatic individuals has low sensitivity and specificity.9 Although the 2019 Primary Prevention of Cardiovascular Disease Guidelines do not comment on functional or invasive testing in asymptomatic individuals with a high CAC score, the 2009 Appropriate Use Criteria for Cardiac Radionuclide Imaging report gives a level A recommendation for obtaining a stress test in asymptomatic individuals with CAC score ≥400.10 In addition, the 2013 update of the 2009 document also considers stress imaging appropriate for patients with CAC score >100. However, there have been no large randomized controlled trials or observational studies that have evaluated the utility of functional or invasive testing in asymptomatic individuals free of ASCVD with high CAC scores. Theoretically, early detection and revascularization of ischemia producing lesions in asymptomatic patients with high-risk coronary calcification without proven ASCVD might reduce the future risk of major adverse cardiovascular events.

03

Conditions studied

  • Coronary Atherosclerosis Due to Calcified Coronary Lesion

Keywords

  • Non-invasive stress test
  • Coronary calcification
  • Agatston score
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must be at least 19 years of age. ② Asymptomatic patients with high-risk coronary calcium (Agatston Score ≥ 400)

Exclusion criteria

Exclusion Criteria:

  • Documentation of objective evidence of inducible ischemia before enrollment

    • Presence of significant coronary artery stenosis (≥ 70% diameter stenosis) confirmed by coronary angiography or coronary computed tomography angiography before enrollment

      • History of coronary revascularization procedure ④ Pregnancy or breast feeding ⑤ Non-cardiac co-morbid conditions are present with \<1 year or that may result in protocol non-compliance (per site investigator's medical judgment) ⑥ Unwillingness or inability to comply with the procedures described in this protocol.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
3,000 participants (estimated)

Study arms

  • Experimental
    Routine stress testing

    In this group, the preselected functional stress testing (exercise electrocardiography, stress echocardiography, nuclear imaging, or stress cardiac magnetic resonance imaging) will be performed within three months (± 2 months) according to the practice pattern of each participating center.

    Diagnostic Test: Non-invasive stress test

  • Active comparator
    As-needed stress testing

    In this group, optimal medical treatment will be performed by current guidelines without further testing. A stress test will be performed only when new symptoms (exertional chest pain or dyspnea) occur that may clinically suggest significant coronary artery disease.

    Diagnostic Test: Medical treatment without further testing

Interventions

  • Diagnostic testNon-invasive stress test

    Nuclear imaging, stress echocardiography, exercise electrocardiography, stress cardiac magnetic resonance imaging

  • Diagnostic testMedical treatment without further testing

    Optimal medical treatment for primary prevention.

06

What researchers measure

Primary outcomes

  1. Occurrence of major adverse cardiovascular events

    a composite of death from cardiovascular causes, myocardial infarction, unplanned hospitalization leading to an urgent revascularization procedure, or heart failure hospitalization

    Time frame: up to 4.5 years of median follow-up

Secondary outcomes

  1. cardiovascular death

    death from cardiovascular causes

    Time frame: up to 4.5 years of median follow-up

  2. myocardial infarction

    myocardial infarction

    Time frame: up to 4.5 years of median follow-up

  3. unplanned hospitalization leading to an urgent revascularization procedure

    unplanned hospitalization leading to an urgent revascularization procedure

    Time frame: up to 4.5 years of median follow-up

  4. heart failure hospitalization

    heart failure hospitalization

    Time frame: up to 4.5 years of median follow-up

  5. all-cause death

    death from any causes

    Time frame: up to 4.5 years of median follow-up

  6. a composite of death from cardiovascular cause or myocardial infarction

    a composite of death from cardiovascular cause or myocardial infarction

    Time frame: up to 4.5 years of median follow-up

  7. any hospitalization

    any hospitalization

    Time frame: up to 4.5 years of median follow-up

  8. performing revascularization procedure

    performing revascularization procedure

    Time frame: up to 4.5 years of median follow-up

  9. performing invasive coronary angiography procedure

    performing invasive coronary angiography procedure

    Time frame: up to 4.5 years of median follow-up

  10. stroke

    stroke

    Time frame: up to 4.5 years of median follow-up

  11. bleeding

    Bleeding Academic Research Consortium type 2-5

    Time frame: up to 4.5 years of median follow-up

  12. total medical cost

    total medical cost

    Time frame: up to 4.5 years of median follow-up

07

Study locations

1 of 1 sites recruiting
  • SamsungMedicalCenter
    Seoul, 06351, Korea, Republic of
    Recruiting
    • Seunghyuk Choi, PhMD · Contact82-2-3410-3437
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Jun 2029, 71 months after the start.

Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 71 months is above that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2023
First posted
Apr 3, 2023
StartActual
Jul 3, 2023
Primary completionEst.
Jun 30, 2029
CompletionEst.
Dec 31, 2029
Last update
Jan 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05796739
Responsible party
Seung-Hyuk Choi (Professor, Samsung Medical Center) — Principal investigator
First posted
Apr 3, 2023
Start date
Jul 3, 2023
Primary completion
Jun 30, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Jan 14, 2025

Study contacts

Seung-Hyuk Choi, MD
Contact
sh1214.choi@samsung.com
82-2-3410-3419
Ki Hong Choi
Contact
cardiokh@gmail.com
82-2-3410-6653
Seung-Hyuk Choi, MD
principal investigator · Samsung Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion